IL-12 promotes anti-tumor immunity due to its role attracting and activating natural killer cells, T helper 1 (Th1) and cytotoxic T lymphocytes (CD8+), whereas IL-23 promotes the activity of regulatory T lymphocytes, expansion of T-helper 17 cells (Th17), angiogenesis and reduces cytotoxic CD8+ T lymphocytes in the TME. The gene discussed is CD8A; the disease is neoplasm.